Biological Evaluation of 3-Aminoisoquinolin-1(2H)-one Derivatives as Potential Anticancer Agents by Potikha, Lyudmyla et al.
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2021, VOLUME 09, ISSUE 02)  
52 
 
Biological Evaluation of 3-Aminoisoquinolin-1(2H)-one Derivatives as Potential 
Anticancer agents 
Lyudmyla M. Potikhaa*, Volodymyr S. Brovaretsb, Victor V. Zhirnovb 
a Department of Chemistry, Taras Shevchenko National University of Kyiv,  
Volodymyrska Street, 64/13, Kyiv 01601, Ukraine 
b V. P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine,  
1 Murmanska St., Kyiv, 02094, Ukraine 
potikha.l.m@gmail.com 
 
Keywords: 1-isoquinolinone, anticancer activity, growth inhibitor, cytostatic activity, selectivity. 
Anticancer activity of a series of 3-(hetaryl/aryl)amino substituted isoquinolin-1(2H)-ones has been 
studied within the international scientific program “NCI-60 Human Tumor Cell Lines Screen”. 
Screening was performed in vitro on 60 cell lines of lungs, kidneys, CNS, ovaries, prostate, and breast 
cancer, epithelial cancer, leukemia, and melanoma. The most effective compounds were those with 
thiazolyl or pyrazolyl substituent at 3-amino group and had no substituents at C(4) of the isoquinoline 
cycle. We identified a new lead compound, 3-(1,3-thiazol-2-ylamino)isoquinolin-1(2H)-one 12, 
which effectively prevents tumor cell growth (average lg GI50 = -5.18, lg TGI = -4.1, lg LC50 > -4.0) 
with good selectivity. 
________________________________________________________________________________ 
Introduction 
Cancer is one of the main worldwide public 
health concerns. According to the World Cancer 
Report published by the World Health 
Organization in 2020, cancer is one of the 
leading causes of premature death [1]. The 
number of people that are diagnoses with cancer 
every year in Europe will increase from the 
current 3.5 million to more than 4.3 million by 
2035. Therefore, there is an urgent need to pay 
much attention to update and modify leading 
drugs in terms of medicinal chemistry and drug 
design in order to provide more potent and 
effective therapies. One of the ways to solve this 
problem is to use the hybrid drugs design 
strategy which tries to find solutions for 
undesired properties of the current drug such as 
drug resistance, drug–drug interactions, and 
known side effects, just to mention a few. It also 
provides hybrid structures that are capable of 
interacting with multiple targets simultaneously 
with improved efficacy. In essence, the aim of 
molecular hybridization is to produce a single 
chemical entity through combination of two or 
more distinct pharmacophore subunits present in 
the structures of two or more known bioactive 
derivatives. For example, pyrazole and thiazole 
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derivatives can be cited as examples of the 
successful application of this strategy [2-6]. 
 
Figure 1. Structures of lead anticancer isoquinoline 
derivatives. 
The aim of the current work was to study 
the anticancer activity of hybrid structures based 
on isoquinoline. In recent years, the isoquinoline 
scaffold has gained recognition as a helpful and 
promising scaffold for the design and 
development of effective anticancer drugs. Due 
to distinct and compelling therapeutic properties, 
natural and synthetic derivatives of isoquinolin-
1(2H)-one have been widely investigated in 
medicinal and organic chemistry. One such 
example is isoquinolinone alkaloids derived 
from plants of the Amaryllidaceae family – 
narciprimine (1) and narciclasine (2) depicted in 
Figure 1 [7]. The latter, in the NCI sixty cell line 
anticancer drug screen exhibited a mean IC50 
value of 0.046 μM in vitro. 3-Aryl substituted 
isoquinolinones (3, R = H, Alk) displayed 
diverse anticancer activities against different 
human cancer cell lines (A549, SK-OV-3, SK-
Mel-2, HCT-15, XF-498) comparable to that of 
doxorubicin [8]. A series of 2,3-diaryl 
isoquinolinone derivatives 3 (R = Ar) exhibited 
significant antiproliferative against MCF-7 
breast cancer cells and potential anti-
angiogenesis effects in vivo via ERa and 
VEGFR-2 dependent mechanisms [9]. Through 
review of literature, we found that some 
phosphatase inhibitors (Cdc25B, IC50 = 
0.77÷13.66 M) [10, 11] with isoquinolin-l-one 
scaffold bear 3-(hetaryl/aryl)amino or 3-
benzylamino fragments (4). The method of 
synthesis of a number of Aurora kinase 
inhibitors (5) is also based on 3-(pyrazol-3-
ylamino)-isoquinolin-1(2H)-ones [12]. The 
strong activity in suppressing proliferation and 
growth of glioblastoma cells [13], colorectal 
(SW620, HT29, GI50 = 23.8÷24.13 M) [14] 
and CNS (SF-295, GI = 55%) [15] human cancer 
cell lines was found for condensed derivatives 
having a 3-aminoisoquinolinone moiety (6). The 
unsaturated 5H-benzo[4,5]imidazo[1,2-
b]isoquinolin-1-one (7) exhibited significant 
Cdc25B inhibition (IC50 = 5.3 M) [11]. In this 
context, the consolidation of the 3-
aminoisoquinolinone template and novel 
carbo/heteroaromatic rings as novel 
pharmacophores seems to be promising for 
obtaining highly effective anticancer drugs. 




Figure 2. General scheme for the synthesis of isoquinolinone derivatives and compounds selected for in vitro testing. 
 
Earlier [16], we have developed a simple 
and convenient method for the synthesis of 3-
aminoisoquinolin-1(2H)-ones (I) from 2-
(cyanomethyl)benzoic acid that made possible 
the variation of the substituent at the 3-amino 
group (Figure 2).  
The unique electronic nature of the 3-
aminoisoquinolinone moiety allowed 
regiospecific substitution on the enamine moiety 
of the molecules, such as acylation at either the 
C(4) or the 3-N positions [17]. This reaction 
allowed producing a series of 3-
(hetaryl/aryl)amino-isoquinolinones and their 
acyl derivatives (II) and the study of their in 





1(2H)-ones 8,9 [16] and 3-(hetarylamino)-
isoquinolin-1(2H)-ones 10-12 [16], 4-(4-
ethoxybenzoyl)-3-(hetarylamino)isoquinolin-
1(2H)-ones 13-15 [17] and N-(4-fluorophenyl)-
N-(1-oxo-1,2-dihydro-3-isoquinolinyl)-4-
ethoxybenzamide 16 [17] were synthesized 
following the procedures described in the 
corresponding cited sources. 
In vitro Anticancer Screening  
In vitro anticancer screening 
methodology as well as data interpretation rules 
are described in details at the NCI Development 
Therapeutics Program site [18]. 
 
Results and discussion 
The structures of the 3-
aminoisoquinolin-1(2H)-ones were submitted to 
US National Institute of Health, and the nine 
compounds 8-12 and 13-16 (Figure 2) were 
selected for evaluation of their antiproliferative 
activity within an international scientific 
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program. These compounds (8-16) were granted 
NSC codes, viz., NSC 776637 ÷ NSC 776641, 
and NSC 776643 ÷ NSC 776646, respectively. 
The elected compounds were submitted to in 
vitro anticancer assay against a full panel of 60 
cancer cell lines taken from different tissues 
(lungs, kidneys, CNS, ovaries, prostate, breast 
cancer, epithelial cancer, leukemia, and 
melanoma). The compounds were tested at a 
single dose concentration of 10-5 М. Growth 
percentage (GP) of cancer cells compared to the 
control (in the absence of a chemical substance, 
100%) was determined [19-22]. 
Isoquinolinone derivatives 8-16 exhibit 
different levels of anticancer activity depending 
on the substituents at the 3-amino group and at 
C(4) (Table 1). It has been shown that 3-
hetarylamino derivatives 10-12 are the most 
active against cancer cells in a wide range of cell 
lines.  
The 1,3-thiazol-2-ylamino derivative 12 
was the most potent of all the derivatives tested, 
with mean GP value of 49.57% for the majority 
of cell lines. It showed to be selective towards 
the breast cancer sub-panel, being active against 
all the corresponding cell lines. The most 
sensitive were MDA-MB-468 and MCF7 cell 
lines with GP 10.72% and 26.62%, respectively. 
Other cell lines that showed more than 70% 
growth inhibition in the micro molar range were 
UO-31 (GP 22.78%) and SK-MEL-5 (GP 
22.08%) belonging to the renal cancer and 
melanoma sub-panels respectively. Also, 
compound 12 showed significant inhibition of 
most of the leukemia, lung, CNS, renal and 
breast cancer cell lines with GP less than 50%. It 
is worthy to note that the thiazol-2-ylamino 
derivative 12 showed good selectivity towards 
the colon, melanoma and ovarian cancer sub-
panels. 
1,3-Dimethyl-1H-pyrazol-5-yl (10) and 
1,3,5-trimethyl-1H-pyrazol-4-yl (11) 
isoquinolinones, unlike the thiazolyl derivative 
12, showed higher selectivity level towards 
cancer cells of all sub-panels, but with higher 
mean GP value of 59.51% and 61.68%, 
respectively. Replacement of the thiazole with 
pyrazole in compounds 10 and 11 maintained the 
antitumor activity against most of the cell lines 
of leukemia and breast cancer sub-panels. The 
most sensitive are RPMI-8226 (leukemia, GP 
34.33% (10) and 28.68% (11)) and MDA-MB-
468 (breast cancer, GP 19.94% (10) and 15.70% 
(11)). Pyrazolyl derivatives 10 and 11 showed 
high effectiveness against ovarian OVCAR-4 
cell line with GP values of 30.45% and 18.20%, 
respectively. The dimethylpyrazolyl derivative 
10 had a lethal effect on renal A498 cell line (GP 
-3.00%) and inhibited the growth of melanoma 
SK-MEL-5 cells by more than 70% (GP 
25.26%). At the same time, the 
trimethylpyrazolyl derivative 11 showed the 
opposite result: lethal effect on melanoma SK-
MEL-5 cell line (GP -12.06%) and GP of 
25.60% against renal A498 cells. In addition, 
compounds 10 and 11 proved to have a 
comparable effect on the SF-295 cell line of 
CNS cancer with GP values of 40.97% and 
40.21%, respectively.  
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Table 1. Mitotic activity (GP) of the 3-aminoisoquinolin-1(2H)-one derivatives 8-16 
towards NCI 60 cell lines at the 10-5 M concentration 
Cell line name 8 9 10 11 12 13 14 15 16 
Leukemia 
CCRF-CEM – – 47.31 56.48 43.13 – – 66.59 – 
HL-60(TB) – – 76.26 – 48.51 – – – 51.48 
K-562 – – 47.23 41.21 49.27 – – 52.95 – 
MOLT-4 – – 50.93 57.97 30.19 70.00 – 41.92 70.87 
RPMI-8226 – – 34.33 28.68 30.30 – 78.96 40.58 – 
SR – – 59.37 38.72 47.84 – – 66.44 – 
Non-Small Cell Lung Cancer 
A549/ATCC – – 59.38 58.23 54.69 – – 68.00 – 
HOP-62 – – 64.13 65.22 49.89 – – – – 
NCI-H226 – – 59.51 54.54 44.97 – – – – 
NCI-H23 – – 46.32 42.19 50.20 – – – – 
NCI-H322M – – 79.19 78.97 57.37 – – – – 
NCI-H460 – – 70.47 75.59 66.98 – – 75.50 – 
NCI-H522 – – nt 36.21 42.28 68.59 61.18 55.16 39.68 
Colon Cancer 
COLO 205 – – 76.77 – 61.01 – – 75.68 – 
HCC-2998 – – – – 61.42 – – – – 
HCT-116 – – 58.56 52.17 52.60 – – 69.24 – 
HCT-15 – – 63.27 70.68 44.44 – – 74.72 – 
HT29 – – nt 78.58 55.21 – – 71.19 – 
KM12 – – 67.91 78.19 50.48 – – 71.49 – 
SW-620 – – – – 78.85 – – – – 
CNS Cancer 
SF-268 – – 78.96 72.71 58.62 – – 73.04 – 
SF-295 – – 40.97 40.21 47.57 – – 69.72 – 
SF-539 – – 52.13 75.91 45.07 – – – – 
SNB-19 – – – 69.33 45.45 – – 71.05 – 
SNB-75 – – 64.51 64.44 45.61 77.98 – 70.15 – 
U251 – – 67.79 69.53 36.12 – – 71.03 – 
Melanoma 
LOX IMVI – – 47.20 69.35 50.88 – – – – 
M14 – – 70.38 64.78 56.36 – – 73.03 76.33 
MDA-MB-435 – – 68.89 61.42 48.07 – – 77.36 – 
SK-MEL-2 – – nt – 72.60 – – – – 
SK-MEL-28 – – – – – – – – – 
SK-MEL-5 – 77.47 25.26 -12.06 22.08 – – 42.60 79.71 
UACC-257 – – 53.52 48.81 55.00 – – – – 
UACC-62 – – 53.99 67.76 51.34 72.56 – 65.87 64.92 
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Table 1. (Contd.) 
Cell line name 8 9 10 11 12 13 14 15 16 
Ovarian Cancer 
IGROV1 – – 78.16 78.49 42.80 – – – – 
OVCAR-3 – – 58.43 50.36 33.18 – – 74.84 – 
OVCAR-4 – – 30.45 18.20 40.97 – – 66.05 – 
OVCAR-5 – – – – – – – – – 
OVCAR-8 – – 57.87 55.31 46.51 – – 61.00 70.11 
NCI/ADR-RES – – 70.79 69.97 57.30 – – 64.62 – 
SK-OV-3 – – – – 52.41 – – – – 
Renal Cancer 
786-0 – – 65.52 65.03 75.74 – – – – 
A498 – – -3.00 25.60 35.19 77.76 63.45 65.98 – 
ACHN – – 72.93 69.95 65.46 – – – – 
CAKI-1 – – 66.59 67.37 48.41 – – – – 
RXF 393 – – 64.65 59.43 45.86 – – 65.60 – 
SN12C – – 57.25 68.09 42.49 – – 67.22 – 
TK-10 – – nt 62.59 48.06 – – – – 
UO-31 77.45 – 32.51 50.28 22.78 43.33 – 46.51 78.76 
Prostate Cancer 
PC-3 – – 58.96 79.43 52.77 64.41 – 58.19 – 
DU-145 – – 71.58 66.69 68.66 – – 79.83 – 
Breast Cancer 
MCF7 – 68.83 33.10 52.14 26.62 72.31 78.93 68.12 – 
MDA-MB-231/ATCC – – 41.93 54.19 31.45 – – 66.08 77.50 
HS 578T – – 71.50 75.26 61.98 – – 79.63 – 
BT-549 – – 46.35 41.70 36.39 – – 67.39 – 
T-47D – – 42.27 45.05 36.00 – – 66.67 – 
MDA-MB-468 – 78.74 19.94 15.70 10.72 77.42 67.73 51.97 – 
Mean GP 99.72 102.14 59.51 61.68 49.57 89.49 95.13 73.55 90.31 
–: GP more than 80%, nt: not tested 
 
Replacement of the azolyl fragment with 
azolylmethyl as in compounds 8 and 9 leads 
either to a sharp decrease (growth inhibition < 
20%) or to a complete loss of the antitumor 
activity (Table 1), which may be attributed to 
restricted conformation of compounds 8 and 9 on 
the receptor binding site due to an increase in the 
spatial volume of the substituent at the 3-amino 
group. 
A similar effect was noted in an earlier 
study [11] evaluating the requirements of 3-
anilinoisoquinolinone scaffold for the inhibition 
of the in vitro phosphatase activity of 
recombinant human Cdc25B. Thus, the retention 
of a relatively low inhibitory activity of 
isoquinolinone derivative 9 towards some breast 
cancer cell lines (MCF7, MDA-MB-468) and 
melanoma (SK-MEL-5) is probably due to the 
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presence of another strong pharmacophore 
(pyrazolyl fragment) in the molecule. 
The unique ‘enamine-like’ structure of the 
isoquinolinone core provides an additional area for 
diversification. Therefore, several compounds (13-
16) among the readily available 4-acyl and 3-N-acyl 
substituted derivatives of 3-aminoisoquinolinones 
[17] with an additional pharmacophore – p-
ethoxybenzoyl fragment – were selected for 
evaluation of their antiproliferative activity. 
However, the introduction of a 4-(p-ethoxybenzoyl) 
substituent proved to be detrimental to the 
inhibitory activity for all tested compounds, similar 
to that observed for 3-[(4-
methylphenyl)amino]isoquinolinone with an 
unsubstituted 4-benzoyl group [11]. Preliminary in 
vitro antitumor screening revealed that 
unsubstituted 3-[(4-fluorophenyl)amino] and 3-[(4-
pyridyl)amino] derivatives of isoquinolinone 
showed good inhibition [11], while their benzoyl 
derivatives 13 and 16 turned out to be inactive for 
most of the cancer cell lines excepted a few of them. 
The most sensitive were leukemia HL-60(TB) and 
lung cancer NCI-H522 cell lines for compound 16 
with GP 51.48% and 39.68%, respectively. Renal 
UO-31 cell line was sensi-tive to compound 13 with 
GP value of 43.33%.  
Benzoylated thiazolyl derivative 14 is also 
almost completely inactive against most of the 
cancer cell lines. The value of its growth inhibition 
exceeded 30% in only three cases: lung cancer NCI-
H522, renal A498 and breast cancer MDA-MB-468 
cell lines. Pyrazolyl derivative 15 displayed the 
most potent overall antiproliferative activity among 
the 4-benzoyl derivatives tested, with mean GP 
value of 73.55%. It exhibited a more than 50% 
inhibition for some of the cell lines belonging to 
different tumor sub-panels: leukemia cells MOLT-
4 and RPMI-8226 giving GP values of 41.92%, and 
40.58%, respectively, melanoma cells SK-MEL-5 
with GP a value of 42.60%, and renal cancer cells 
UO-31 with a GP value of 46.51%. 
Among all the 4-benzoyl derivatives tested, 
the sharpest decrease of the antitumor activity was 
observed for the thiazolyl derivative 14 as 
compared to its unsubstituted analogue 12, and may 
be attributed to the presence of two acceptor 
substituents in the molecule. In the case of 
compound 14, this leads to deeper changes in the 
distribution of electron density in the isoquinolinone 
moiety due to the formation of an ortho-quinone 
structure favored by an intramolecular hydrogen 
bond between the 3-imino and 4-enol fragments 
[17], as shown in Scheme 1. 
Scheme 1. Tautomeric forms of thiazolyl derivative 14. 
Thus, Table 1 revealed that compound 12 is the 
most active towards numerous cancer cell lines 
belonging to different tumor sub-panels. Therefore, 
it was selected in advanced assay against a panel of 
approximately 60 tumor cell lines at 10-fold dilution 
of five concentrations (10-4-10-8 М), the set of which 
was identical to that for the pre-screening stage 
(Table 2). The results were compared with 5-
fluorouracil (5-FU) as reference drug (Table 2), 
which has been used as a standard for more than 40 
years [23, 24]. 
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Table 2. Parameter values (lg) of the anticancer activity of compound 12 and 5-fluorouracil as reference compound 





GI50 TGI GI50 GI50 TGI GI50 
Leukemia 
CCRF-CEM -5.07 >-4.00 -5.01 MOLT-4 -5.27 >-4.00 -6.45 
HL-60(TB) -4.82 >-4.00 -5.60 SR -4.98 >-4.00 -5.01 
K-562 -5.28 >-4.00 -5.45     
Non-small cell lung cancer 
A549/ATCC -4.89 >-4.00 -6.80 NCI-H23 -5.30 >-4.00 -6.75 
HOP-62 -5.48 -4.19 -7.28 NCI-H322M -5.11 >-4.00 -6.67 
HOP-92 -5.57 -5.06 -6.64 NCI-H460 -4.64 >-4.00 -6.03 
NCI-H226 -5.18 >-4.00 -6.96 NCI-H522 -4.98 >-4.00 -6.80 
Colon cancer 
COLO 205 -5.09 >-4.00 -6.80 HT29 -4.48 >-4.00 -6.75 
HCC-2998 -4.63 >-4.00 -7.28 KM12 -5.04 >-4.00 -6.67 
HCT-116 -5.16 >-4.00 -6.64 SW-620 -4.42 >-4.00 -6.03 
HCT-15 -5.39 >-4.00 -6.96     
CNS cancer 
SF-268 -5.26 >-4.00 -5.80 SNB-19 -5.29 >-4.00 -5.42 
SF-295 -5.15 >-4.00 -6.64 SNB-75 -5.69 -4.97 -4.10 
SF-539 -5.42 >-4.00 -7.20 U251 -5.41 -4.12 -6.04 
Melanoma 
LOX IMVI -5.16 >-4.00 -6.61 SK-MEL-28 -4.80 >-4.00 -5.99 
MALME-3M >-4.00 >-4.00 -7.29 SK-MEL-5 -5.41 -4.54 -6.33 
M14 -5.21 >-4.00 -6.01 UACC-257 -4.94 >-4.00 -5.45 
MDA-MB-435 -5.16 >-4.00 - UACC-62 -5.32 >-4.00 -6.28 
SK-MEL-2 -4.83 -4.07 -4.25     
Ovarian cancer 
IGROV1 -5.28 >-4.00 -5.91 OVCAR-8 -5.32 >-4.00 - 
OVCAR-3 -5.26 >-4.00 -7.80 NCI/ADR-RES -5.15 >-4.00 -4.66 
OVCAR-5 -4.01 >-4.00 -5.76 SK-OV-3 -5.29 >-4.00 -5.91 
Renal cancer 
786-0 -4.95 >-4.00 -6.14 RXF 393 -5.57 -5.00 -5.58 
A498 -5.85 -4.63 -6.40 SN12C -5.11 >-4.00 -6.30 
ACHN -5.21 >-4.00 -6.53 TK-10 -5.07 -4.05 -5.95 
CAKI-1 -5.14 >-4.00 -7.14 UO-31 -5.86 >-4.00 -5.85 
Prostate cancer 
PC-3 -5.41 >-4.00 -5.63 DU-145 -4.61 >-4.00 -6.44 
Breast cancer 
MCF7 -5.86 >-4.00 -7.10 BT-549 -5.69 -4.78 -4.97 
MDA-MB-231/ATCC -5.79 -4.17 -5.18 T-47D -5.72 >-4.00 -5.09 
HS 578T -5.41 >-4.00 -5.01 MDA-MB-468 -5.94 - - 
a Data for 5-fluorouracil are given according to [25] 
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The high antitumor potential of 
compound 12 has been confirmed by a 
significant level of inhibition (average lg GI50 = 
-5.18) and cytostatic (average lg TGI = -4.1) 
effects for some cell lines. However, the level of 
cytotoxic effect lg LC50 of all cell lines was not 
high and exceeded average value of -4.00. The 
cell lines that were the most sensitive to the tested 
compound 12 were: HOP-92 non-small cell lung 
(lg GI50 = -5.57, lg TGI = -5.06), SNB-75 CNS 
(lg GI50 = -5.69, lg TGI = -4.97), A498 renal (lg 
GI50 = -5.85, lg TGI = -4.63), RXF 393 renal (lg 
GI50 = -5.57, lg TGI = -5.00), MDA-MB-
231/ATCC breast (lg GI50 = -5.79, lg TGI = -
4.17) and BT-549 breast (lg GI50 = -5.69, lg TGI 
= -4.78). 3-(Thiazolylamino)isoquinolinone 12 
showed the greatest activity against most of the 
cell lines of the lung, colon, CNS, ovarian, renal 
and breast cancer sub-panels.  
Overall, the activity of 5-fluorouracil 
(average lg GI50 = -6.10 [25]) is higher than 
isoquinolinone 12. Nevertheless, compound 12 
demonstrates a higher activity than standard 5-
fluorouracil does against: SNB-75 (CNS); SK-
MEL-2 (melanoma); NCI/ADR-RES (ovarian); 
MDA-MB-231/ATCC, HS 578T, BT-549 and T-
47D (breast). Moreover, compounds 12 and 5-
fluorouracil proved to have similar efficiency 
against the renal RXF 393 and UO-31 cell lines. 
Additionally, compound 12 demonstrated a 
remarkable activity towards breast MDA-MB-
468 with lg GI50 value of -5.97. 
We have performed COMPARE [26] 
analyses for the active compound 12 in order to 
investigate the similarity of its cytotoxicity 
pattern with those of known anticancer standard 
agents, NCI active synthetic and natural 
compounds, which are present in public available 
databases [27]. According to the Chaddock scale 
[28], compound 12 has a low positive 
COMPARE correlation of GI50 vector with 
triciribine phosphate (r = 0.35). Moreover, 
matrix COMPARE using TGI vector showed 
moderate positive correlations with triciribine 
phosphate and spirohydantoin mustard (r = 0.6 
for both) (Figure 3).  
 
Figure 3. Structures of NCI anticancer standard agents. 
The mechanism of action for triciribine 
(NCS 280594) includes its prevention Protein 
kinase B (AKT) membrane translocation [29], 
and specifically its binding to the PH domain of 
AKT, thereby blocking its recruitment to the 
membrane, leading to subsequent inhibition of 
AKT phosphorylation in tumours [30, 31]. The 
mechanism of antineoplastic activity of 
spirohydantoin mustard (NCS 172112), like for 
all other alkylating agents, lies in its ability to 
alkylate DNA guanine nucleobases and, thus, to 
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prevent uncoupling of DNA strands, which is a 
required step for any cell to divide [32]. 
Obviously, the antiproliferative activity of 3-
(thiazolylamino)isoquinolinone 12 is not 
associated with the ability to alkylate DNA 
guanine nucleobases. Taken together, this 
suggests that the most likely molecular target for 
3-(thiazolylamino)isoquinolinone 12 is Protein 
kinase B. However, the absence of a very high 
positive correlation with the above compounds 
requires further experimental studies for the 
correct interpretation of the results obtained. 
 
Conclusions 
Herein we demonstrated the in vitro 
anticancer activity of some 3-
(hetaryl/aryl)aminoisoquinolin-1(2H)-ones 
against the NCI 60 human cancer cell lines. 
Therein, the nature of the substituent at the C(4) 
and 3-N positions of isoquinoline cycle critically 
affects the level of activity. More favorable is the 
presence of a thiazolyl or a pyrazolyl substituent 
at the 3-amino group. In the same time, the 
presences of acceptor substituents at C(4) 
position or at 3-amino group and an increase in 
the spatial volume of the substituent at the 3-
amino group are detrimental to the inhibitory 
activity. Although the critical biochemical 
targets of 3-hetarylaminoisoquinolin-1(2H)-ones 
have not been identified, they show an interesting 
antiproliferative profile against different human 
tumor-derived cell lines, especially: 3-[(1,3-
dimethyl-1H-pyrazol-5-yl)amino] and 3-[(1,3,5-
trimethyl-1H-pyrazol-4-yl)amino]isoquinolin-
1(2H)-ones 10 and 11 against RPMI-8226 
(leukemia), MDA-MB-468 (breast cancer), 
OVCAR-4 (ovarian), A498 (renal) and SK-
MEL-5 (melanoma) cell lines. We identified a 
new lead compound, 3-(1,3-thiazol-2-
ylamino)isoquinolin-1(2H)-one 12, which 
efficiently prevents tumor cell growth of MDA-
MB-468 and MDA-MB-231/ATCC (breast 
cancer), UO-31 and A498 (renal), SNB-75 
(CNS) and HOP-92 (non-small cell lung) cell 
lines. Thus, the 3-aminoisoquinoline series 
provides an attractive new core structure for 
additional analysis and optimization. 
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